Main Cause Of Hospital Admission Research Articles

Regulatory axis of circular RNA DTNB, microRNA-485-5p, and myeloid cell leukemia 1 attenuates inflammation and apoptosis in caerulein-treated AR42J cells.

Acute pancreatitis (AP) is an inflammatory disease of the pancreas and the main cause of hospital admissions for gastrointestinal diseases. Here, the work studied the circular RNA DTNB/microRNA-485-5p/MCL1 axis in AP and hoped to unravel the related mechanism. Caerulein exposure replicated an AP model in AR42J cells, and caerulein-mediated expression of circDTNB, miR-485-5p, and MCL1 was recorded. After exposure, cells were intervened with transfection plasmids and tested for LDH release, apoptosis, and inflammation. To determine the interwork of circDTNB, miR-485-5p, and MCL1, prediction results and verification experiments were conducted. Caerulein exposure reduced circDTNB and MCL1, while elevated miR-485-5p levels in AR42J cells. Upregulating circDTNB protected AR42J cells from caerulein-induced LDH cytotoxicity, apoptosis, and inflammation, but circDTNB upregulation-induced protections could be muffled by inhibiting MCL1. On the contrary, downregulating circDTNB further damaged AR42J cells under caerulein exposure, however, this phenomenon could be partially rescued after silencing miR-485-5p. miR-485-5p was mechanistically verified to be a target of circDTNB to mediate MCL1. Overall, the circDTNB/miR-485-5p/MCL1 axis protects inflammatory response and apoptosis in caerulein-exposed AR42J cells, promisingly identifying circDTNB as a novel molecule for AP treatment.

Atrial Fibrillation Prevalence Rates and Its Association with Cardiovascular-Kidney-Metabolic Factors: SIMETAP-AF Study.

Background and Objectives: Atrial fibrillation (AF) is the most frequent arrhythmia and the main cause of hospital admissions for cardioembolic stroke. The SIMETAP research project aims to update the prevalence rates of cardiovascular, renal, or metabolic factors and to evaluate their respective associations with factors that could be related. The present study aims to assess the AF prevalence rates in an adult population and its association with cardiovascular-kidney-metabolic (CKM) factors. Materials and Methods: This cross-sectional observational study was conducted in a primary care setting, with a population-based random sample of 6588 people aged 18.0-102.8 years. Crude and adjusted prevalence rates of AF were calculated. The associations of CKM factors with AF were assessed using bivariate and multivariate analysis. Results: The age- and sex-adjusted prevalence rates of AF were 2.9% in the overall adult population, 6.1% in the population aged ≥50 years, and 12.9% in the population aged ≥70 years, with no significant differences by sex. AF prevalence in the population under 50 years of age barely reached 1‰. Heart failure (HF), hypertension, chronic kidney disease (CKD), stroke, low HDL-cholesterol, and prediabetes were independent CKM factors associated with AF in the overall population, as were the same factors, except prediabetes, in the population ≥50 years old (p < 0.001). High or very high vascular risk was present in 92.4% [95% CI: 89.1-95.7]) of the population with AF. Conclusions: The adjusted prevalence rate of AF in the population aged 50 years or older was 6.1%, twice that of the overall adult population and half that of the population aged 70 years or older. The main independent CKM factors associated with AF were HF, stroke, CKD, hypertension, and low HDL-cholesterol.

Clinical treatment with bisphosphonates and surgical treatment of osteogenesis imperfecta

Introduction: Osteogenesis imperfecta is characterized by presenting an alteration in the synthesis of collagen that mainly affects the structure of the bone and its hardness, causing bone fragility and abundant deformations. Generally, the main cause of hospital admission is long bone fractures, which must be treated very diligently to avoid permanent sequelae, with rapid consolidation of these fractures being a pathognomonic characteristic. Being a genetic disease, a definitive treatment is unknown, therefore, conventional treatment is symptomatic and a specific procedure will be carried out for each case, which will help maintain an acceptable lifestyle for these patients. General objective: Describe the conventional treatment in patients diagnosed with osteogenesis imperfecta.Methodology: Bibliographic review type study, where the information will be collected from scientific search engines Scopus, Taylor and Francis, Web of Science, PubMed, Elsevier, and Redalyc; The following keywords and with the Boolean operators OR, AND and NOT.Conclusions: Since its first description, there have been improvements in the classification, and in terms of specific symptomatic treatment they have visibly improved, however, there is no curative basic treatment to date.

Efficacy of a Telemonitoring System as a Complementary Strategy in the Treatment of Patients With Heart Failure: Randomized Clinical Trial.

Episodes of decompensation are the main cause of hospital admissions in patients with heart failure. For this reason, the use of mobile apps emerges as an excellent strategy to improve coverage, real-time monitoring, and timeliness of care. ControlVit is an electronic application for early detection of complications studied within the context of a tertiary university hospital. Patients were randomized to the use of ControlVit versus placebo, during a 6-month follow-up. The primary outcome was the difference in numbers of readmissions and deaths for heart failure between both groups. One hundred forty patients were included (intervention = 71, placebo = 69), with an average age of 66 years old; 71% were men. The main etiology of heart failure was ischemic (60%), whereas the main comorbidities were arterial hypertension (44%), dyslipidemia (42%), hypothyroidism (38%), chronic kidney disease (38%), and diabetes mellitus (27%). The primary outcome occurred more frequently in the control group: readmission due to decompensation for heart failure (control group n = 14 vs intervention group n = 3; P = .0081), and death (control group n = 11 vs intervention group n = 3; P = .024). In heart failure patients, ControlVit is a useful and supplementary tool, which reduces hospital admissions due to episodes of decompensation.

Sodium-Glucose Cotransporter Type 2 Inhibitors Use in Elderly Polypathological Patients with Acute Heart Failure: PROFUND-IC Registry.

Background/Objectives: Heart failure (HF) is a highly prevalent clinical syndrome with serious morbidity and mortality. Furthermore, acute heart failure (AHF) is the main cause of hospital admission in people aged 65 years or more. Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) have been shown to improve the survival and quality of life in patients with HF regardless of left ventricular ejection fraction (LVEF). Our aims were to describe the characteristics of adults with multiple pathologies admitted with acute heart failure as the main diagnosis and of the population treated with SGLT2is, as well as to evaluate if their use was associated with lower readmission and mortality rates. Methods: A prospective study of patients from the PROFUND-IC registry who were admitted with AHF as the main diagnosis was conducted. Clinical and analytical characteristics were analyzed, as well as readmissions and mortality. Descriptive and bivariate analyses of the sample between those taking SGLT2is and those who were not were performed, using the chi-square test for qualitative variables and Welch's test for quantitative measures, as well as the Fisher and Wilcoxon tests as indicated for nonparametric tests. Kaplan-Meier curves were constructed to analyze the readmission and mortality of patients at 12 months based on SGLT2i treatment. Finally, a propensity score matching was performed, guaranteeing that the observed effect of the drug was not influenced by the differences in the characteristics between the groups. Results: There were 750 patients included: 58% were women, and the mean age was 84 years. Functional class II according to the NYHA scale predominated (54%), and the mean LVEF was 51%. SGLT2 inhibitors were prescribed to only 28% of patients. Most of the patients were men (48.6% vs. 39.8%, p = 0.029), they were younger (82 vs. 84 years, p = 0.002), and their LVEF was lower (48% vs. 52%, p < 0.001). Lower mortality was observed in the group treated with SGLT2is, both during baseline admission (2.4% vs. 6.9%, p = 0.017) and at the 12-month follow-up (6.2% vs. 13%, p = 0.023); as well as a lower readmission rate (23.8% vs. 38.9%, p < 0.001). After the propensity score matching, a decrease in the 12-month readmission rate continued to be observed in the group treated with SGLT2is (p = 0.03). Conclusions: SGLT2is use was associated with lower readmission rates at the 12-month follow-up in older adults with multiple pathologies admitted with acute heart failure.

MAIN CAUSES OF HOSPITAL ADMISSIONS OF CHILDREN AND ADOLESCENTS AGED 0 TO 18 IN THE CITY OF CAMPINA GRANDE/PB, FROM 2020 TO 2022: A CROSS-SECTIONAL STUDY

Introduction: Pediatric diseases and their main causes of hospitalization are directly related to simple outpatient measures, sensitive to basic care. However, there were changes in the epidemiological and clinical scenario of hospitalizations for these diseases, with the advent of the covid-19 pandemic. Objective: To study the causes of hospital admissions for children and adolescents aged 0 to 18 years old and their evolution from 2020 to 2022, in the city of Campina Grande/PB. Methodology: This is a descriptive, cross-sectional and retrospective study, carried out with data obtained from the Hospital Information System (SIH), searching for the main causes of hospital admissions for children and adolescents admitted to pediatric reference services in Campina Grande. The variables used were biological characteristics (sex, age) and clinical characteristics (number of hospitalizations; length of stay; hospital discharge conditions; deaths). Results: The main cause of hospitalization in the group of pediatric diseases in the three years studied was pneumonia due to non-specific microorganisms (PNM), corresponding to 9.9% of hospitalization cases in 2020; 12.5% in 2021 and 15.8% in 2022. Another important highlight was lymphoid leukemia (ALL), which accounted for 2.6% of cases in 2020; 4.2% in 2021 and 4.3% in 2022. In the group of neonatal and infant diseases, the main causes of hospitalizations were disorders related to short-term pregnancy and low birth weight, represented by 10.3% of cases in 2020, 7.4% in 2021 and 6.4% in 2022. Discussion: The consequences of the pandemic were the progressive increase in the incidence of respiratory diseases, with the return of classes and exposure to viruses and bacteria, after isolation prolonged social. In addition to the progressive increase in the incidence of premature births, directly related to teenage pregnancy, considered a public health problem. And the incidence of ALL, which was underdiagnosed in 2020, as most resources were directed to the pandemic. Conclusion: the pandemic impacted pediatric epidemiology, increasing the number and profile of hospitalizations, mainly due to respiratory diseases and oncological diseases.

External validation of the new REACT-HF score for heart failure prediction in patients with atrial fibrillation

Abstract Background Heart failure (HF) represents the main cause of hospital admissions and deaths among atrial fibrillation (AF) patients, but precise risk prediction tools are lacking. Recently, the REACT-HF score has been developed to predict incident HF hospitalizations or cardiovascular (CV) death within 2-years based on 12 variables (sex, age, height, creatinine clearance, diabetes, vascular disease, valvular heart disease, heart rate and rhythm, left ventricular hypertrophy and intraventricular conduction delay). Purpose The aim of the present study was to externally validate the REACT-HF score within the Swiss-AF and BEAT-AF cohorts, and to investigate whether this score model can be improved by adding biomarkers (hs-CRP, NT-proBNP, hs-TNT). Methods We included 2’599 AF patients from the Swiss- and BEAT-AF cohorts without prior history of HF, with at least one follow-up and with all baseline variables needed for the REACT-HF score. To validate the score, we estimated a Cox model with the original score as the only predictor. We further explored whether the predictive performance of the REACT-HF score model could be improved by adding any combination of the above listed biomarkers. The primary outcome was incident HF hospitalization or CV death. Secondary outcomes included the individual components of the primary outcome and all-cause mortality. Results Mean age was 70.2 years, 29.1% were female and 54.8% had paroxysmal AF. The mean CHA2DS2-VASc score was 2.7 (+/- 1.6). The most frequent comorbidities were hypertension (65%), diabetes (12%), vascular disease (23%) and coronary artery disease (36%). Most patients (1’883) presented a very low REACT-HF score below 0.05 (72.4%), 530 patients between 0.05 and below 0.1 (20.4%) and 186 had a risk score of 0.1 and above (7.2%). In the validation set, 380 (14.6%), 471 (18.1%), 511 (19.7%) 561 (21.6%) and 676 (26.0%) patients were categorized in the lowest to the highest quintiles based on the original score`s quintiles. Figure 1 shows the Kaplan-Meier survival curves for the primary endpoint of first HF hospitalization or CV death by quintiles of the REACT-HF score, applied in our pooled cohort. And Figure 2 shows the Kaplan-Meier curves for the 1st HF hospitalization. The incidence rates at 2-year follow-up per 100 patient-years of the primary outcome (0.39, 0.59, 1.58, 3.97, 7.53), HF hospitalization (0.39, 0.49, 1.38, 2.75, 6.26), CV death (0.0, 0.10, 0.20, 1.29, 2.12), and all cause-death (0.10, 0.49, 0.78, 2.29, 4.24) all increased gradually among the quintiles of risk score. The estimated c-statistic for the composite primary outcome was 0.764 (approximate 95% CI, 0.723-0.806). The best biomarker enhanced-model within our cohort was the model including hs-CRP and NT-proBNP (c-statistic 0.810). Conclusions The REACT-HF score discriminates well for prediction of HF hospitalization and CV death in a contemporary AF population and can be improved by including NT-pro-BNP and hs-CRP.

Factors related to mortality in patients with stage 5 chronic kidney disease on dialysis with COVID-19: An exploratory case series analysis.

Different studies describe the clinical profile and factors that could explain the evolution and outcome of patients with chronic kidney disease and COVID-19. This study aims to evaluate the factors related to the mortality of patients with stage-5 chronic kidney disease on chronic dialysis hospitalized for COVID-19 at the Hospital Nacional Arzobispo Loayza from April to December 2020. Retrospective case series and exploratory analysis were performed. Patients with stage-5 chronic kidney disease on dialysis, older than 18 years, and hospitalized for COVID-19 disease were included. Hospital medical records were the primary data source. A total of 105 medical records were reviewed. 57 were male (54.3%), with a mean age of 58.6 years (standard deviation: 14.3). Eighty-four patients survived (80%), and 21 died (20%). The main cause of hospital admission, present in 80 patients (76.2%), was respiratory failure; the mean hospital stay was of 11.8 days (SD: 7.8). In the bivariate analysis: patients with moderate to severe COVID-19, overweight and obesity, increased levels of leukocytes, D-dimer, ferritin, C-reactive protein, lactate dehydrogenase, as well as, decreased levels of lymphocytes, bicarbonate and arterial oxygen pressure/inspired oxygen fraction were related to mortality risk. In multivariate analysis, only severe COVID-19 disease (OR 1.48; 95% CI 2.24 to 7.77), C-reactive protein > 10 mg/dL (OR: 9.72; 95% CI: 1.41 to 18.58), and arterial oxygen pressure/inspired oxygen fraction ≤ 150 millimeters of mercury (OR: 10.23; 95% CI: 5.87 to 36.06) were factors associated with poor survival. In patients with stage-5 chronic kidney disease hospitalized for COVID-19, severe COVID-19 disease, C-protein reactive levels > 10 milligrams per deciliter, arterial oxygen pressure / inspired oxygen fraction ≤ 150 millimeters of mercury and severe COVID-19 disease were the main factors related to mortality.

Efficacy of controlvit as a complementary strategy in reducing hospitalizations in patients with heart failure. Randomized clinical trial

Abstract Introduction In patients with heart failure, the main cause of hospital admissions is due to episodes of decompensation, which are associated with an increase in the costs and resources needed for care; they have a negative impact on the quality of life and prognosis of the disease. Therefore, it is necessary to design, evaluate and implement alternatives to achieve efficient follow-up and monitoring, improving adherence to treatment and helping identify decompensation episodes that facilitate their early treatment, so new hospital admissions can be avoided. For this reason, the use of information and communication technologies (apps) is emerging as an excellent strategy for the possibility of improving coverage, real-time monitoring and timeliness of care. ControlVit® is an electronic application that allows permanent, real-time monitoring of biomedical measurements for early detection of complications. Objective To determine the efficacy of ControlVit® as a complementary strategy in reducing hospital admissions in patients in a heart failure program. Methodology A randomized, placebo-controlled, open-label clinical trial was conducted, (n=140), included patients with heart failure under controlled clinical follow-up in a structured heart failure program, into NYHA FC II–IV, capable of handling smartphones and with permanent internet connectivity. All patients were provided with educational elements, a scale and a blood pressure monitor to enter clinical data and a symptom questionnaire necessary for follow-up. The patients were randomized to 2 groups: intervention: use of ControlVit® vs. placebo, with a 6-month follow-up. The primary outcome was the difference in readmissions for heart failure between the 2 groups. Patients on the waiting list for heart transplantation or use of ventricular assist devices were excluded. All participants signed informed consent and the protocol was approved by the institutional ethics committee. Results A total of 140 patients were included in the study (intervention = 71, placebo = 69), with an average age of 66 years, 71% were men, the main etiology of heart failure was ischemic (60%), the main comorbidities were arterial hypertension (44%), dyslipidemia (42%), hypothyroidism (38%), chronic kidney disease (38%), and diabetes mellitus (27%). During follow-up, there were 6 deaths (3 in each group) and 17 readmissions (3 in the intervention group and 14 in the control group). After adjustment for comorbidities, HR 0.72 CI95 (0.52; 0.92), p=0.0325 was found. Conclusion In patients with heart failure, ControlVit® is a useful and complementary tool for follow-up, which reduces hospital admissions due to episodes of decompensation. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): German Saldarriega award.Javeriana University

Echocardiography in Heart Failure with Preserved Ejection Fraction: From Primary Care to Tertiary Hospitals

Introduction Heart failure (HF) is a highly prevalent and incident clinical syndrome that mostly affects older adults. It is one of the main causes of hospital admission, which is a strong prognostic marker, considering that approximately 50% of hospitalized patients will be readmitted within 6 months. HF with preserved ejection fraction (HFpEF) is hemodynamically defined as an inability of the heart to meet adequate metabolic demands under normal filling pressures. This concept is fundamental, given that patients with normal left [...]

Abstract 13478: Observatory of Hospitalizations and Mortality in 37 Cardiology Departments in 17 Sub-Saharan African Countries: The February Study From African Research Network

Non-communicable diseases represent the second common cause of death in Sub-Saharan Africa (SSA) accounting for 50% of deaths in several countries. Furthermore, 80% of cardiovascular diseases (CVD) deaths occurs in low and middle-income countries. Data regarding the characteristic of patients with CVDs are scarce in SSA. To describe hospital admission for CVD and care components in 17 in SSA countries. We conducted a transversal and longitudinal study in CV departments of 37 hospitals (public and private) in 17 SSA countries. The February study is an ongoing observatory included all inpatients in February from each year since 2016. Data including socio-demographic and clinical characteristics, CV risk factors, causes of admission, medication and length of stay were collected during hospitalization by the investigating physicians. Patient wealth index was assessed by physicians as low, middle and high according to patient capacity to afford hospitalization. All analyses were performed with random effect on countries and through scripts developed in the R software 4.0.3. Overall, 4360 in-hospital patients were included in the February study, the mean age was 56.7 ± 16.8 years, and 56.4 % were men. Individual wealth index was low, middle and high in 1158 (27.7%), 1812 (43.4%) and 1203 (28.8%) patients, respectively. The main cause of hospital admission was heart failure (41.5%)(figure) followed by acute coronary syndrome (11.9%) and stroke (11%). Causes of admission varied significantly across countries and over years. Overall, 73.8% of patients had at least one CV risk factors and hypertension (≥ 140±90mmHg) was noticed in 55.2% of patients. Average length of stay was 10 days. Mortality rate was 11% and did not vary over time but was significantly different according to patient wealth index (p&lt;0.05) consistent by sex, age, and type of hospital.The February observatory provides reliable data in SAA. High rate of hospitalization mortality remain open to investigation.

Efficacy of controlvit as a complementary strategy in reducing hospitalizations in patients with heart failure. Randomized clinical trial

Abstract Introduction In patients with heart failure, the main cause of hospital admissions is due to episodes of decompensation, which are associated with an increase in the costs and resources needed for care; they have a negative impact on the quality of life and prognosis of the disease. Therefore, it is necessary to design, evaluate and implement alternatives to achieve efficient follow-up and monitoring, improving adherence to treatment and helping identify decompensation episodes that facilitate their early treatment, so new hospital admissions can be avoided. For this reason, the use of information and communication technologies (apps) is emerging as an excellent strategy for the possibility of improving coverage, real-time monitoring and timeliness of care. ControlVit® is an electronic application that allows permanent, real-time monitoring of biomedical measurements for early detection of complications. Objective To determine the efficacy of ControlVit® as a complementary strategy in reducing hospital admissions in patients in a heart failure program. Methodology A randomized, placebo-controlled, open-label clinical trial was conducted, (n=140), included patients with heart failure under controlled clinical follow-up in a structured heart failure program, into NYHA FC II–IV, capable of handling smartphones and with permanent internet connectivity. All patients were provided with educational elements, a scale and a blood pressure monitor to enter clinical data and a symptom questionnaire necessary for follow-up. The patients were randomized to 2 groups: intervention: use of ControlVit® vs. placebo, with a 6-month follow-up. The primary outcome was the difference in readmissions for heart failure between the 2 groups. Patients on the waiting list for heart transplantation or use of ventricular assist devices were excluded. All participants signed informed consent and the protocol was approved by the institutional ethics committee. Results A total of 140 patients were included in the study (intervention = 71, placebo = 69), with an average age of 66 years, 71% were men, the main etiology of heart failure was ischemic (60%), the main comorbidities were arterial hypertension (44%), dyslipidemia (42%), hypothyroidism (38%), chronic kidney disease (38%), and diabetes mellitus (27%). During follow-up, there were 6 deaths (3 in each group) and 17 readmissions (3 in the intervention group and 14 in the control group). After adjustment for comorbidities, HR 0.72 CI95 (0.52; 0.92), p=0.0325 was found. Conclusion In patients with heart failure, ControlVit® is a useful and complementary tool for follow-up, which reduces hospital admissions due to episodes of decompensation. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): German Saldarriega award.Javeriana University

Epidemiological Characterization and the Impact of Healthcare-Associated Pneumonia in Patients Admitted in a Northern Portuguese Hospital

Pneumonia is one of the main causes of hospitalization and mortality. It’s the fourth leading cause of death worldwide. Healthcare-associated infections are the most frequent complication of healthcare and affect hundreds of millions of patients around the world, although the actual number of patients affected is unknown due to the difficulty of reliable data. The main goal of this manuscript is to describe the epidemiological characteristics of patients admitted with pneumonia and the impact of healthcare-associated pneumonia (HCAP) in those patients. It is a quantitative descriptive study with retrospective analysis of the clinical processes of 2436 individuals for 1 year (2018) with the diagnosis of pneumonia. The individuals with ≤5 years old represented 10.4% (n = 253) and ≥65 were 72.6% (n = 1769). 369 cases resulted in death, which gives a sample lethality rate of 15.2%. The severity and mortality index were not sensitive to the death event. We found 30.2% (n = 735) individuals with HCAP and 0.41% (n = 59) with ventilator-associated pneumonia (VAP). In only 59 individuals (2.4%) the agent causing pneumonia was isolated. The high fatality rate obtained shows that pneumonia is a major cause of death in vulnerable populations. Moreover, HCAP is one of the main causes of hospital admissions from pneumonia and death and the most pneumonias are treated empirically. Knowledge of the epidemiology characterization of pneumonia, especially associated with healthcare, is essential to increase the skills of health professionals for the prevention and efficient treatment of pneumonia.

Predictive Modeling of Poor Outcome in Severe COVID-19: A Single-Center Observational Study Based on Clinical, Cytokine and Laboratory Profiles.

Pneumonia is the main cause of hospital admission in COVID-19 patients. We aimed to perform an extensive characterization of clinical, laboratory, and cytokine profiles in order to identify poor outcomes in COVID-19 patients. Methods: A prospective and consecutive study involving 108 COVID-19 patients was conducted between March and April 2020 at Hospital Clínico Universitario de Valladolid (Spain). Plasma samples from each patient were collected after emergency room admission. Forty-five serum cytokines were measured in duplicate, and clinical data were analyzed using SPPS version 25.0. Results: A multivariate predictive model showed high hepatocyte growth factor (HGF) plasma levels as the only cytokine related to intubation or death risk at hospital admission (OR = 7.38, 95%CI—(1.28–42.4), p = 0.025). There were no comorbidities included in the model except for the ABO blood group, in which the O blood group was associated with a 14-fold lower risk of a poor outcome. Other clinical variables were also included in the predictive model. The predictive model was internally validated by the receiver operating characteristic (ROC) curve with an area under the curve (AUC) of 0.94, a sensitivity of 91.7% and a specificity of 95%. The use of a bootstrapping method confirmed these results. Conclusions: A simple, robust, and quick predictive model, based on the ABO blood group, four common laboratory values, and one specific cytokine (HGF), could be used in order to predict poor outcomes in COVID-19 patients.

TỶ LỆ NHẬP VIỆN VÀ YẾU TỐ LIÊN QUAN ĐẾN THỜI GIAN NẰM VIỆN CỦA NHỮNG BỆNH NHÂN HÔ HẤP VÀ TIM MẠCH TẠI BỆNH VIỆN BẠCH MAI GIAI ĐOẠN 2018 - 2019

Objectives: study presents proportions of hospital admissions for respiratory diseases (RD) and cardiovascular (CVD) and risk factors of length of hospital stay (LOS) for these diseases in Bach Mai hospital during 2018 - 2019. Participants and Methods: Cross-sectional study. Results: This study included a total of 80.897 hospital admissions due to RD and CVD in Bach Mai hospital during 2018 – 2019, which accounted for 25,33% and 74,67% of the admissions. Patients with age below 35 years old accounted for 13.93% of the total RD and CVD admissions. Other age groups were 36- to 59-year-olds (29,89%) and older or equal to 60-year-olds (56,18%). About 56.64% of the hospital admissions were male and 43,36% of them were female. Patients living in Hanoi accounted for 30,34%. we found that the proportion of prolonged LOS (&gt;7 days) was significantly higher among people living in other provinces from Hanoi (p &lt; 0,001). Additionally, people older than 35 years old showed a higher proportion than younger ones (p &lt; 0,001). In CVD groups, this proportion was higher among females (p &lt; 0,001). Conclusion: Generally, number of RD and CVD admissions increased in 2019 when comparing to 2018. The majority of patients, who visited in 2019, lived in Northern areas of Viet Nam. CVD and RA are main causes of hospital admissions in Bạch mai Hospital. Age, sex, and location of living associated with prolonged LOS (&gt;7 days) in Bach Mai Hospital during 2018 - 2019. Keywords: Length of hospital stay, Respiratory diseases, Cardiovascular diseases

Exercise-Based Rehabilitation Delivery Models in Comorbid Chronic Pulmonary Disease and Chronic Heart Failure.

Among the most prevalent multimorbidities that accompany the aging process, chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF) stand out, representing the main causes of hospital admissions in the world. The prevalence of COPD coexistence in patients with CHF is higher than in control subjects, given the common risk factors associated with a complex process of chronic diseases developing in the aging process. COPD-CHF coexistence confers a marked negative impact on mechanical-ventilatory, cardiocirculatory, autonomic, gas exchange, muscular, ventilatory, and cerebral blood flow, further impairing the reduced exercise capacity and health status of either condition alone. In this context, integrated approach to the cardiopulmonary based on pharmacological optimization and non-pharmacological treatment (i.e., exercise-based cardiopulmonary and metabolic rehabilitation) can be emphatically encouraged by health professionals as they are safe and well-tolerated, reducing hospital readmissions, morbidity, and mortality. This review aims to explore aerobic exercise, the cornerstone of cardiopulmonary and metabolic rehabilitation, resistance and inspiratory muscle training and exercise-based rehabilitation delivery models in patients with COPD-CHF multimorbidities across the continuum of the disease. In addition, the review address the importance of adjuncts to enhance exercise capacity in these patients, which may be used to optimize the gains obtained in these programs.

One-year intravenous immunoglobulin replacement therapy: efficacy in reducing hospital admissions in pediatric patients with Inborn Errors of Immunity

ObjectivesTo compare the frequency of hospitalization in children with Inborn Errors of Immunity with antibody deficiency previous to intravenous immunoglobulin (pre- IVIG) with a one-year period after initial IVIG (post-IVIG). MethodsMedical reports of 45 patients during an eight-year period were reviewed from 2018 to 2019. Wilcoxon-test was used for related samples. ResultsForty-five children were included in the study, aged 29–249 months of age, and most of them (64.4%) were males. Median ages at onset symptoms and at diagnosis were 6 and 73 months old, respectively. Specific antibody deficiency and unclassified hypogammaglobulinemia were the predominant diagnoses (31.1% and 17.8%, respectively). X-linked agammaglobulinemia, Hyper IgE syndrome, Hyper IgM, transient hypogammaglobulinemia of infancy, and Common Variable Immunodeficiency (CVID) were also reported, in a low frequency. Forty-four (97.8%) patients were hospitalized before IVIG, and 10 patients (22.2%) after. Annual mean hospital admission reduced from 2.5 to 0.5, pre and post-IVIG, respectively (p < 0.0001). Mean length of stay (LOS) reduced from 71 to 4.7 days/year (p < 0.0001) in general ward and in the PICU from 17.2 days/year to zero (p < 0.0002). Pneumonia was the main cause of hospital admission with a reduction in the number of episodes per patient from an average of 2.2–0.1 per year (p < 0.001). Concomitant use of antibiotic prophylaxis did not influence the number of hospital admission. ConclusionOne-year intravenous IVIG significantly decreased the number of hospitalizations and length of stay in children with impaired antibody production. Social and economic impacts would be required.

MO317DETERMINANTS OF LENGHT OF HOSPITAL STAY (LOS) IN NEPHROTIC SYNDROME PATIENTS

Abstract Background and Aims Generalized edema, non responsive to oral diuretics, is one of the main causes of hospital admission for nephrotic syndrome patients. Although hospital length of stay (LOS) may vary widely, in 2017 the average LOS in acute-care hospitals was lower than 8 days in OECD countries. The aim of the present study was to determine the factors commonly associated with a longer LOS in patients admitted for edema due to nephrotic syndrome in the Nephrology Unit of ICS Maugeri, Pavia, Italy Method In this retrospective study we reviewed the medical records of all patients admitted for nephrotic syndrome between 2012-2020 in the Nephrology Unit of ICS Maugeri. Inclusion criteria were the following: age between 18-85 years of age; severe edema non responsive to oral, low dose diuretics; patients with heart failure, serum creatinine &amp;gt; 3.5 g/dl or on dialysis treatment were excluded from the study. Patients were divided into two groups according to the length of stay: ≤ 7 days or ≥ 8 days. Age, gender, serum protein concentration, creatinine, and hemoglobin; serum cholesterol and tryglicerides, urinary protein excretion rate; types of glomerular disease, weight loss were recorded. Student T tests and one-way Anova were performed to evaluate the differences between the means. Results 60 patients (42 male, 18 female) with a total number of hospital accesses of 93 were enrolled in the study. Mean age was 66.8 ± 13.07 years. Average LOS was 9.02 ± 7.4 days. Protein excretion rate was 6.7 ± 3.6 g/24 hours at the admission and was not statistically changed at discharge. Mean total serum protein and creatinine concentration at the admission were 4.7 ± 0.8 g/dl and 1.8 ± 1.1 mg/dl respectively. Patients with LOS &amp;lt; 7 days were younger (64 ± 11.9 vs 69 ± 13.6 years, p &amp;lt;0.05), had a lower serum creatinine (1.55 ± 0.92 vs 2.08 ± 1.2 mg/dl, p&amp;gt;0.001) and a significantly higher total serum protein concentration (5.02 ± 0.77 vs 4.65 ± 0.76 g/dl, p&amp;lt; 0.001) and haemoglobin (12.6 ± 1.8 vs 11.4 ± 1.8 g/dl, p&amp;lt; 0.05) compared to patients with longer LOS. Proteinuria was not significantly different between the two groups (6.27 ± 3.36 vs 7.1 ± 3.9 g/24 hours, p= NS). While serum cholesterol and tryglicerides were higher in the group of patients with longer LOS, weight loss was similar in the two groups at discharge. Although the difference was not significant, the group with longer hospitalization had a greater number of patients with a diagnosis of focal segmental glomerulosclerosis (FSGS) Conclusion Our results demonstrate that age, total serum protein concentration, serum creatinine, higher lipids and probably the diagnosis of FSGS may affect the hospital length of stay of patients with nephrotic syndrome admitted for severe edema. A more aggressive diuretic treatment may be needed in elderly nephrotic syndrome patients with lower GFR and total serum protein concentration.

Internações hospitalares em idosos no extremo Norte do Brasil

O objetivo deste estudo foi analisar as principais causas das internações hospitalares em idosos no estado de Roraima no ano de 2019. Trata-se de um estudo descritivo, de abordagem quantitativa, utilizando a base de dados do Sistema de Informações Hospitalares do Sistema Único de Saúde. A maior frequência de hospitalização foi do gênero masculino (59,9%). As principais causas das internações entre mulheres e homens foram semelhantes, contudo houve a inversão da ordem de algumas causas. Em ambos os gêneros, as doenças do aparelho circulatório e as do aparelho respiratório foram as mais frequentes, aumentando sua ocorrência com o avanço da idade. Estes resultados podem auxiliar nas estratégias e ações em saúde direcionada a população idosa, com atenção ao manejo das doenças crônicas que representam um desafio a longo prazo.

Thyroid Dysfunction in Patients Admitted in Cardiac Care Unit: Prevalence, Characteristic and Hospitalization Outcomes.

IntroductionCardiovascular disease is one of the main causes of hospital admission and mortality, and thyroid dysfunction increases the risk of developing acute or exacerbation of chronic cardiac conditions. The aim of this study is to investigate the prevalence of thyroid hormone abnormality among patients in the cardiac care unit (CCU) patients and its relation to admission diagnosis, clinical, biochemical data, and hospital-related outcomes.MethodsWe conducted a retrospective cohort observational that included adult patients who were admitted to the CCU. We excluded those with known thyroid dysfunction and those who received amiodarone or IV contrast.ResultsA total of 374 patients with a mean age of 62.7+14.7 years old were included. Ischemic changes were observed in 70.6% of the patients based on the admission diagnosis. In comparison to the non-ischemic group, the ischemic group was more likely to be male (P=0.010), to be active/former smokers (P=0.011), to have diabetes (P=0.009), to have diastolic dysfunction (P=<0.001), to have undergone thrombolysis (P=<0.001), and to have been referred to a tertiary center (P=<0.001). Euthyroidism was observed in 57.8% of the patients based on the thyroid function test at admission. Compared to patients with thyroid dysfunction, those with Euthyroidism were more likely to be active/former smokers (P=0.002), to have lower heart rates (P=0.018), to not have chronic kidney disease (P=0.016), to not have heart failure (P=0.006), to have lower thyroid-stimulating hormone (TSH) levels (P=<0.001), and to have lower tricuspid regurgitation (P=0.042).ConclusionThyroid dysfunction is common among patients admitted to the CCU. Non-significant positive correlations between TSH and hospitalization length, tertiary center referral, 30-day readmission, and in-hospital mortality when adjusting for potential confounders.